New hope for slowing deadly lung scarring in scleroderma patients
NCT ID NCT07491523
Summary
This study looks back at the medical records of 35 people with scleroderma who have developed lung scarring. It compares two treatment approaches: a standard two-drug combination versus that same combination plus an extra anti-scarring drug. The goal is to see if adding the third drug helps better preserve lung function over two years, as lung disease is the leading cause of death in scleroderma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of patras
RECRUITINGPátrai, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.